Microport Cardioflow Medtech Corp
HKEX:2160

Watchlist Manager
Microport Cardioflow Medtech Corp Logo
Microport Cardioflow Medtech Corp
HKEX:2160
Watchlist
Price: 0.88 HKD Market Closed
Market Cap: 2.1B HKD

Net Margin
Microport Cardioflow Medtech Corp

-13.7%
Current
-112%
Average
1.8%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-13.7%
=
Net Income
-49.4m
/
Revenue
361.6m

Net Margin Across Competitors

Microport Cardioflow Medtech Corp
Glance View

Market Cap
2.1B HKD
Industry
Health Care

MicroPort CardioFlow Medtech Corp. operates as a holding company with interest in developing medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-02-04. The firm is mainly engaged in the development and commercialization of transcatheter and surgical solutions for valvular heart diseases. The firm's main products include the first-generation transcatheter aortic heart valve implantation (TAVI) product VitaFlow and the second-generation TAVI product VitaFlow II. The firm mainly conducts business within the domestic market.

Intrinsic Value
1.7 HKD
Undervaluation 48%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-13.7%
=
Net Income
-49.4m
/
Revenue
361.6m
What is the Net Margin of Microport Cardioflow Medtech Corp?

Based on Microport Cardioflow Medtech Corp's most recent financial statements, the company has Net Margin of -13.7%.

Back to Top